A PHASE 3, TWO-STAGE, RANDOMIZED STUDY OF MEZIGDOMIDE, CARFILZOMIB, AND DEXAMETHASONE (MEZIKD) VERSUS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-2 | Publicación